
==== Front
J Hepatocell Carcinoma
J Hepatocell Carcinoma
jhc
Journal of Hepatocellular Carcinoma
2253-5969
Dove

494470
10.2147/JHC.S494470
Letter
Predicting Treatment Response and Prognosis in Patients with Hepatocellular Carcinoma after Interventional Therapy [Letter]
Li et al
Li et al
http://orcid.org/0000-0003-4905-2242
Li Hang 1
Shen Xiping 1
Wu Ji 1
1 Department of General Surgery, Suzhou Ninth Hospital Affiliated to Soochow University, Suzhou, Jiangsu Province, People’s Republic of China
Correspondence: Ji Wu, Department of General Surgery, Suzhou Ninth Hospital Affiliated to Soochow University, No. 2666, Ludang Road, Wujiang District, Suzhou, Jiangsu Province, People’s Republic of China, Tel +86-0512-82881248, Email 1968232851@qq.com
17 9 2024
2024
11 17411742
03 9 2024
14 9 2024
© 2024 Li et al.
2024
Li et al.
https://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
funding There is no funding to report.
==== Body
pmcDear editor

With great interest, we read the recent article by Ma et al published in the Journal of Hepatocellular Carcinoma.1 This significant study provides insights into the association of the oxidative stress-related genes (OSRGs) with treatment response and prognosis in patients with hepatocellular carcinoma (HCC) after transarterial chemoembolization (TACE). A prognostic nomogram was developed for survival prediction. We appreciated the rigorous efforts and valuable contributions of this study. However, we would like to raise the following comments:

Firstly, the Cox regression model is a widely accepted method for its clinical utility. However, its use in scenarios with potential competing risks may inadvertently lead to risk overestimation. Traditional survival analysis techniques might not fully account for the influence of other events on the primary study endpoint. A competing risk model could provide a more holistic viewpoint for outcome prediction in this study, especially when candidate variables are potentially interrelated.2

Secondly, the potential confounding factors should be evaluated. Commendably, the authors adjusted for potential covariates. However, a further inclusion of other potential confounders may further enhance the stability and reliability of the results. Considering studies have shown differences in HCC prognosis among different races, it can be inferred that race might be an important covariate affecting the clinical outcome.3–5 Race of patients in the TCGA-LIHC cohort are accessible, and therefore race should also be considered for a more comprehensive assessment of the robustness of these findings.

Last but not least, sex disparity in incidence and tumor aggressiveness was observed in HCC patients.6,7 A separate analysis for this subgroup would be a valuable addition to these findings. In addition, in order to apply this model in clinical practice as soon as possible, it is proposed to develop a user-friendly software and/or website.

This article is a significant step forward in our understanding of the relationship between OSRGs and treatment response and clinical outcome in HCC patients. A more comprehensive prediction and further validation could be an intriguing topic for further investigation.

Disclosure

The authors declare no potential conflict of interest in this communication.
==== Refs
References

1. Ma H, Yu T, Li ZC. et al. An Oxidative Stress-Related Prognostic Signature Predicts Treatment Response and Outcomes for Hepatocellular Carcinoma After Transarterial Chemoembolization. J Hepatocell Carcinoma. 2024;11 :1569–1580. doi:10.2147/JHC.S465592 39156675
2. Damen JA, Hooft L, Schuit E, et al. Prediction models for cardiovascular disease risk in the general population: systematic review. BMJ. 2016;353 :i2416. doi:10.1136/bmj.i2416 27184143
3. Islami F, Ward EM, Sung H, et al. Annual Report to the Nation on the Status of Cancer, Part 1: national Cancer Statistics. J National Cancer Inst. 2021;113 (12 ):1648–1669. doi:10.1093/jnci/djab131
4. Gao Y, Xu Y, Wang Y, et al. Clinical features and prognostic factors of patients with inoperable hepatocellular carcinoma treated with chemotherapy: a population-based study. J Gastrointest Oncol. 2024;15 (3 ):1122–1140. doi:10.21037/jgo-24-298 38989427
5. Liao Z, Zhang Q, Yang L, et al. Increased hsa-miR-100-5p Expression Improves Hepatocellular Carcinoma Prognosis in the Asian Population with PLK1 Variant rs27770A>G. Cancers. 2023;16 (1 ). doi:10.3390/cancers16010129.
6. Wands J. Hepatocellular carcinoma and sex. New Engl J Med. 2007;357 (19 ):1974–1976. doi:10.1056/NEJMcibr075652 17989393
7. Huang CY, Tan KT, Huang SF, et al. Study of sex-biased differences in genomic profiles in East Asian hepatocellular carcinoma. Discover Oncol. 2024;15 (1 ):276. doi:10.1007/s12672-024-01131-9
